Cedilla Therapeutics | October 25, 2021
Cedilla Therapeutics a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million. The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures.“We are grateful for the support from our new and existing investors, which reflects the promise of our novel approach to conditionally modulating proteins as well as the unique potential of our lead programs, inhibitors against TEAD and CDK2, two critical but historically undruggable targets,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “With this financing, we plan to accelerate and expand our development efforts by progressing our most advanced programs toward the clinic while continuing to invest in ongoing discovery efforts against additional high value cancer targets.”
Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach and esophageal cancers. The company plans to initiate investigational new drug application-enabling studies for the TEAD program in the first half of 2022 and for the CDK2 program in the second half of 2022.
In conjunction with the financing, Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla’s Board of Directors.
Dr. Glucksmann continued, “We are pleased to welcome Jake to our Board of Directors. He brings a wealth of experience advising companies from the earliest stages of company formation through their maturation into fully integrated biopharmaceutical organizations. We look forward to his many contributions as we continue to grow Cedilla into a clinical-stage organization with a robust and growing portfolio of product candidates.”
“Cedilla brings a new dimension to precision oncology by conditionally modulating proteins in their functional state Preclinical data generated to-date suggest that Cedilla’s lead programs may challenge historical perceptions of TEAD and CDK2 as undruggable targets and could offer patients new options that would be well-tolerated and extremely effective. In addition, Cedilla’s approach, based on a deep understanding of how the cellular context modulates protein activity, could deliver superior inhibitors against a range of other key cancer drivers. I look forward to partnering with the team with the aim to deliver a broad portfolio of small molecule medicines, each with potential profound benefit to patients.”
Jake Simson, Ph.D., Partner at RA Capital Management
About Cedilla Therapeutics
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. x
Cision PR Newswire | August 31, 2020
Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead candidate, BOXR1030, which is on track for near-term entry into the clinic. In addition, Unum will be eligible to receive downstream milestones of up to $3.4 million. The sale to SOTIO will enable it to further advance its goal to develop the next generation of potent immunotherapies for patients with cancer. Unum will retain its antibody coupled T cell receptor (ACTR) technology and continues to explore strategic opportunities for the technology and assets. The sale is final as of August 28, 2020.
Stramsen Biotech, Inc | December 17, 2020
Stramsen Biotech, Inc, a professional group of medication researchers from the Houston, Texas territory comprises of scientists who devote their lives each day to investigating and exploring both the cycles and logical instruments hidden the world we live in today. Colleagues have gotten a few honors and awards for research ventures, with a significant number of their activities and distributions accessible upon demand. Individuals incorporate PhD and University level professors who specialize in chemistry, medication and different biotechnology research projects. This group of experienced researchers has been included widely in clinical examination for more than 20 years.
Stramsen Biotech, Inc has more than six drug/medicine candidates currently in early-stage clinical trials. Two drug/medicine candidates have demonstrated promising outcomes in early clinical preliminaries for treatment of HIV/AIDS. A third drug applicant has additionally demonstrated promising outcomes in early clinical preliminaries for treatment of numerous kinds of wounds and cuts, including diabetic injuries. A fourth medication applicant shows promising outcomes in early clinical preliminaries for treating the basic Flu and Covid-19. The fifth outstanding medication competitor, focusing on ongoing and advance stage malignant growths, has additionally indicated promising outcomes in early clinical preliminaries. Finally, a 6th applicant as an immunization shows promising clinical preliminary outcomes for Newcastle disease, a infection of domestic poultry and other winged creature species with the virulent Newcastle disease virus (NDV).